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International Mexiletine and Placebo Antiarrhythmic Coronary Trial:
I. Report on Arrhythmia and Other Findings
IMPACT RESEARCH GROUP*
The antiarrhythmic effects of the sustained release form
of mexiletine (Mexitil-Perlongets) were evaluated in a
double-blind placebo trial in 630 patients with recent
documented myocardial infarction. The primary re-
sponse variable was based on central reading of 24 hour
ambulatory electrocardiographic recordings and was de-
fined as the occurrence of 30 or more single premature
ventricular complexes in any two consecutive 30 minute
blocks or one or more runs of two or more premature
ventricular complexes in the entire 24 hour electrocar-
diographic recording. Large differences, regarded as
statistically significant, between the mexiletine and pia-
Prevention of sudden cardiac death after myocardial infarc-
tion remains a major challenge. It is generally accepted that
ventricular arrhythmias are a major cause of death in the
patient with myocardial infarction, both before and after
admission to the hospital (1). Because of the strong asso-
ciation between ventricular arrhythmias and the risk of sud-
den cardiac death for such patients, it seems logical to at-
tempt to prevent sudden death by long-term antiarrhythmic
treatment. This latter approach is reinforced by the fact that
observed mortality from acute myocardial infarction has
been declining (2,3), possibly , in part because of prompt
treatment of serious arrhythmias detected by continuous
monitoring of patients with myocardial infarction in coro-
nary care units.
The International Mexiletine and Placebo Antiarrhythmic
Coronary Trial (IMPACT) was initiated to ascertain whether
the sustained release form of mexiletine (Mexitil-Perlongets)
would be effective in reducing the occurrence of ventricular
arrhythmia in patients with recent documented myocardial
infarction. Short-term controlled studies (4,5) had shown
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cebo groups were noted in that end point at months 1
and 4, but only trends were observed at month 12. These
differences were observed even though the serum mex-
iletine levels obtained in this study were generally lower
than those observed in studies that have used the regular
form of the drug. There were more deaths in the mex-
i1etine group (7.6%) than in the placebo group (4.8%)j
the difference was not statistically significant. The in-
cidence of coronary events was similar in both groups.
Previously recognized side effects, particularly tremor
and gastrointestinal problems, were more frequent in
the mexiletine group than in the placebo group.
that mexiletine was effective in reducing the rate of pre-
mature ventricular beats in patients prone to arrhythmias.
These same studies and long-term noncontrolled studies (6,7)
indicated that mexiletine did not induce dangerous side ef-
fects . The sustained release form of mexiletine was selected
for study because it had been demonstrated to yield constant
blood levels with only two doses per day and also had fewer
side effects than the regular form (8). The study was also
designed to study the safety and patient tolerance of the
drug compared with placebo during the first 12 months after
an acute event. The occurrence of both fatal and nonfatal
events was monitored.
It was thought that before embarking on a large scale
secondary prevention study of the sustained release form of
mexiletine , a controlled trial to assess the antiarrhythmic
effects as well as patient tolerance should be undertaken in
a group of patients with moderate mortality risk after myo-
cardial infarction . Results from a study (9) of the regular
form of mexiletine conducted in the United Kingdom in
patients judged to be at high risk after acute myocardial
infarction suggested that high risk patients might not benefit
from prophylactic antiarrhythmic therapy .
Methods
Study organization. Nine clinical centers in Europe and
North America (one in Belgium, one in Canada, two in
France, one in The Netherlands, one in Scotland and three
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in the United States) participated in this trial. To accom-
modate the international nature of the study, there were two
Regional Coordinating Centers-one in Baltimore, Mary-
land for the North American clinics and one in Lyon, France
for the European clinics. All electrocardiograms were read
at one Electrocardiogram Center in Rotterdam , The Neth-
erlands. A Central Laboratory was located in Van Nuys,
California. A Data Audit Center in Chicago, Illinois func-
tioned as a secondary data analysis center and monitored
the performance of the two Regional Coordinating Centers.
The Drug Procurement and Distribution Centers, respon-
sible for coding and packaging the study drugs under the
guidance of the Regional Coordinating Centers, were lo-
cated in Elmsford, New York and Ingelheim, West Germany.
A Planning Board was responsible for the initial devel-
opment of the study protocol and functioned until an in-
dependent Policy Board was established to direct the study .
The Policy Board had final responsibility for the scientific
conduct of the study. It consisted of permanent members
who were not associated with the operation of the trial or
with the sponsor and ex officio members representing the
study leadership. The other administrative units of the study
included a Steering Committee, Executive Committee, Data
Monitoring Committee and Mortality and Morbidity Clas-
sification Committee . The study was financed by a grant
from Boehringer Ingelheim International, Ltd. , Ingelheim ,
West Germany.
Patient eligibility and exclusion criteria. Men aged 30
to 74 years and women aged 45 (to exclude women of child-
bearing potential) to 74 years who were admitted to a hos-
pital coronary care unit in the participating Clinical Centers
and \Ii ho had evidence of a recent myocardial infarction
were screened for eligibility for this study and registered in
the Clinical Center log books. The eligibility and exclusion
criteria were defined with the intent of enrolling patients
with moderate risk of mortality after myocardial infarction
and without regard to the presence or absence of arrhythmia.
The clinic physician considered a patient to have had a
documented myocardial infarction if there was 1) a typical
history and Q/QS changes (on comparison of two recent
electrocardiograms), 2) serum enzyme elevations and Q/QS
changes, or 3) a typical history , serum enzyme elevations
and either (a) Q/QS findings plus ST or T wave abnormal-
ities , or both, (b) ST segment deviations , or (c) T wave
changes. The Minnesota Code for classification of electro-
cardiographic changes was used for this assessment. The
patients who met the diagnostic criteria and who appeared
eligible after a comprehensive medical examination were
invited to participate in the study . If, after a full explanation
of the purposes of the study and its possible risks and ben-
efits . the patient gave written informed consent, a 12 lead
rest electrocardiogram and a 24 hour ambulatory electro-
cardiogram were taken. A baseline examination that in-
volved final assessment of eligibility was completed after
the patient was in a stable condition. This examination was
completed no sooner than 72 hours and no later than 25
days after admission to the hospital.
Conditions that excluded a patient permanently from the
study were: congestive heart failure that could not be con-
trolled by digitalis or diuretic drugs, or both; cardiogenic
shock; Wolff-Parkinson-White syndrome; sick sinus syn-
drome ; Parkinsonism, epilepsy or organic neurologic dis-
order ; history of adverse reaction to mexiletine; history of
hypersensitivity to local anesthetics of the amide type, such
as lidocaine; myocardial infarction resulting from surgery,
angiography, trauma, hypoglycemic shock, infectious en-
docarditis, aortic dissection, embolism with normal coro-
nary arteries or carbon monoxide intoxication; need for ther-
apy with other antiarrhythmic drugs or antianginal drugs
other than long-acting nitrates ; or any condition that was
associated with reduced likelihood of survival or made it
unlikely the patient would adhere to the protocol. A patient
was also ineligible if any of the following conditions were
present at the time of the qualifying examination: complete
left bundle branch block ; heart rate of less than 50 beats/min;
second or third degree atrioventricular (AV) block; symp-
tomatic hypotension or systolic blood pressure of less than
90 mm Hg. If all these conditions were absent for 72 hours
within 25 days of entry into the hospital , the patient was
then eligible to complete the baseline examination.
As soon as the baseline examination was completed, a
request for allocation was sent by telecopier to the appro-
priate Regional Coordinating Center. The Regional Coor-
dinating Center staff reviewed the request for allocation and
if the patient was judged eligible, a treatment allocation was
issued and transmitted immediately to the clinic.
Treatment regimens. Mexiletine capsules and corre-
sponding placebo capsules were administered in a double-
blind manner. Each patient was instructed to take daily one
capsule of assigned medication (either mexiletine, 360 mg,
or placebo) during breakfast and one capsule during the
evening meal. Dosage decreases in both the mexiletine and
placebo groups were to be made by the study physician if
serious side effects occurred. Neurologic or psychologic
side effects, such as parkinsonism or psychotic reactions
required permanent discontinuation. The protocol also rec-
ommended temporary discontinuation of assigned study
medication if any of the following conditions occurred: sec-
ond or third degree AV block , ventricular fibrillation or
symptomatic ventricular tachycardia , congestive heart fail-
ure that could not be controlled by digitalis or diuretic drugs
and prescription of any antiarrythmic drugs (except digitalis)
or any antianginal drugs other than long-acting nitrates.
Study medication did not have to be discontinued if beta-
receptor blocking agents were prescribed. The protocol noted
that available information indicated that the only reported
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adverse effect of the combined use of mexiletine and beta-
receptor blocking agents was the possible occurrence of
bradycardia.
Examination schedule and procedures. Each patient
was asked to return to the clinic for follow-up examinations
at I, 2, 4, 8 and 12 months after entry into the study. Each
visit included a medical history ~ physical examination, local
laboratory tests of urine and blood specimens, assessment
of adherence to study medication and collection of blood
specimens for determination of serum mexiletine levels and
other biochemical determinations at the Central Laboratory.
The occurrence of nonfatal cardiovascular and noncardio-
vascular events was ascertained on the basis of data collected
at these visits. A 12 lead rest electrocardiogram and 24 hour
ambulatory electrocardiogram were obtained at the follow-
up visits completed at 1, 4 and 12 months after entry. A 6
foot (or 2 meter) posteroanterior chest X-ray film was taken
at the visit scheduled 12 months after entry. Urinalysis,
hematocrit and white blood cell count were performed in
the local laboratory of each of the clinical centers.
All electrocardiograms were obtained using Oxford Med-
ilog recorders and were graded at the Electrocardiogram
Reading Center without knowledge of treatment assignment
or clinical findings. The 24 hour electrocardiograms were
analyzed on the Argusl2H system (10), with counts of pre-
mature ventricular complexes, doublets or runs recorded for
each of the forty-eight 30 minute blocks. Additional findings
were reported for the entire 24 hour recording. For quality
control, a trained observer reviewed one 30 minute block
and counted the premature ventricular complexes, doublets
or runs in that block. In addition, a time-stratified random
sample of tapes was submitted for rereading in such a way
that the technician readers did not know the tape had been
read previously.
Primary end points. Review of the published data in-
dicated' that no single set of arrhythmic markers can be
accepted as predictive of sud~en cardiac death (II). It has
been observed (12) that frequent premature ventricular com-
plexes may precede ventricular fibrillation in patients who
are being monitored in the coronary care unit, but others
(13) have been unable to find warning arrhythmias in the
early stages of myocardial infarction based on morphology
or timing of premature ventricular complexes that would
identify patients at high risk of ventricular fibrillation in the
coronary care unit.
One approach to assessing efficacy of antiarrhythmic
therapy has been to measure the reduction in rate of baseline
premature ventricular complexes. This approach could not
be used in IMPACT for two reasons. First, it was anticipated
(and subsequently confirmed by IMPACT data) that the rate
of premature ventricular complexes, at least in the placebo
group, would increase once the patients were discharged
from the hospital, engaged in greater physical activity and
were more exposed to life stresses. Second, IMPACT was
a study of prevention as well as treatment of cardiac ar-
rhythmias and patients were eligible whether arrhythmia was
absent or present.
Arrhythmia response end point. During the planning
phase, the IMPACT investigators defined the primary re-
sponse variable for this study as the occurrence of 30 or
more single premature ventricular complexes in any two
consecutive 30 minute blocks or one or more runs of two
or more premature ventricular complexes in the entire 24
hour electrocardiographic recording assessed on the basis
of the grading of the 24 hour electrocardiogram recordings
at the Electrocardiogram Reading Center. This response
variable is denoted here as frequent or complex cardiac
arrhythmia. Thus, the primary arrhythmia end point in-
cluded arrhythmia variables that could be measured by am-
bulatory monitoring and that were presumed to be predictive
of the occurrence of ventricular fibrillation and, therefore,
presumably predictive of sudden cardiac death. Review of
previously reported studies indicates that this relation has
not been established, although data from the Coronary Drug
Project (14) indicated an excess risk of death, including
sudden death, was associated with the frequency of pre-
mature beats in the rest 12 lead electrocardiogram. The
IMPACT definition of frequent or complex cardiac arrhyth-
mia includes Lown classes 2 (that is, peak rate ~ 30 pre-
mature ventricular complexes/h), 4A (that is, doublets) and
4B (that is, runs of three or more premature ventricular
complexes) (15). Other arrhythmia response variables were
also defined and evaluated in IMPACT.
Reports of hospitalization and mortality were reviewed
by the Mortality and Morbidity Classification Committee
without knowledge of treatment assignment. This committee
classified each event according to previously defined criteria.
Data monitoring. Data reports were reviewed semian-
nually by the Data Monitoring Committee. The reports in-
cluded data on arrhythmia end points, nonfatal and fatal
events, possible side effects, biochemical findings, quality
control and patient adherence to protocol prescription. The
protocol specified that the decision to extend or expand the
study would be based on the analysis of the readings of the
24 hour electrocardiographic recordings obtained at 4 months
and the limited information available for later months in
conjunction with the data on side effects and fatal and non-
fatal events; this decision was to be made approximately I
year after patient recruitment started.
Sample size and randomization. The minimal number
of patients was 600; the goal for each clinic was 75 patients.
This sample provided a reasonable chance (power = 0.89)
of detecting a difference if, after 4 months of treatment, the
rate of frequent or complex cardiac arrhythmia in placebo-
treated patients was 30% and the rate in mexiletine-treated
patients was 18% (40% reduction). With this sample size,
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there \\ as only a small chance (power = O. 17) of detecting
a 20 to 25% reduction in the I year mortality if the mortality
rate in the placebo group was approximately 10%.
Separate randomization schedules were prepared for each
clinical center and were designed to balance, at specified
intervals throughout the period of recruitment, the number
of patients assigned to the mexiletine and placebo groups.
There were no other stratification variables.
Study timetable. Patient recruitment started February
15, 19~ I and terminated March 31, 1982; 630 patients were
enrolled (317 assigned to mexiletine and 313 to placebo).
Nineteen percent of the patients entering the participating
clinica I centers' coronary care units with a diagnosis of
myocardial infarction were actually enrolled in the study.
After review of all available data in April 1982, the Data
Monitoring Committee concluded that an expanded long-
term secondary prevention study was not warranted and
recommended that follow-up study of all patients be ter-
minated. The Policy Board endorsed this recommendation,
which was then implemented by the study investigators. In
the penod between May I, 1982 and August 31, 1982, all
survivmg patients were scheduled for a final visit at which
study treatment was discontinued. Any event including death
that occurred before the date of the final scheduled visit was
counted for the assessment of treatment effects. Each sur-
viving patient was seen in October or November 1982, at
which time he or she was given a summary of the study
results and informed of the treatment received during the
study.
Statistical methods. Mexiletine-placebo differences in
the proportion of fatal and nonfatal events were assessed
by calculating Z values, that is, the difference between the
proportions in the two groups divided by the standard error
of the difference. The results of life table analyses, calcu-
lated using the product-limit method (16), are also reported
for mortality and incidence of coronary events. The Cox
regression method (17) was used to compare the treatment
group iife table curves for mortality and incidence of coro-
nary i : vents both unadjusted and adjusted for baseline dif-
ferenc es. The variables used for the Cox adjusted analyses
were:hosen by a method using the variables that produced
the greatest amount of adjustment to the treatment difference
(18). In general, these variables are those most highly as-
sociated with the end point and those differentially distrib-
uted between the two treatment groups. A test for homo-
geneity of log odds ratios (19) was used to evaluate the
interaction of mexiletine treatment with each of 141 baseline
variahles.
All patients were included in the analysis of the results
and were always counted ill the treatment group to which
they were originally randomized.
The primary end point, as just defined, was frequent or
complex cardiac arrhythmia based on the 24 hour ambu-
latory electrocardiograms taken at months 4 and 12 after
entry; month 4 to assess short-term effects and month 12 to
assess long-term effects. Month 4 was selected rather than
month I because it was expected that the patients would be
more stable 4 months after the acute event than at I month.
The test for comparison of two proportions was carried out
to evaluate the efficacy of mexiletine compared with placebo
treatment with respect to the primary end point. For the
primary end point, as well as for total mortality, a Z value
in excess of ± 1.96 (p < 0.05) was considered to be sta-
tistically significant. The mexiletine and placebo treatments
were also compared with respect to the primary end point
at month I and for a number of additional measures of
cardiac arrhythmia (for example, total premature ventricular
complex count, total number of runs and other 24 hour
electrocardiographic measurements at months I, 4 and 12)
as well as for multiple measures of drug safety and toxicity.
The numerous statistical tests increase the likelihood that a
statistically significant difference will be observed when
there is no true difference between the two treatment groups.
The need for adjustment of the critical Z value is generally
accepted, but no single or simple solution is available.
Therefore, the investigators decided in the planning phase
that for response variables other than the primary end points
just mentioned, Z values in excess of ± 3.0 would be con-
sidered statistically significant, and those in the range ± 2.6
to 3.0 would be considered of borderline significance.
Since loss of information because of death could obscure
the true effects of mexiletine on cardiac arrhythmia, one
analysis attempts to take account of all deaths. In this anal-
ysis, patients who died and did not have electrocardio-
graphic changes before death were also counted as having
frequent or complex cardiac arrhythmia.
Results
Baseline comparability of treatment groups. The dis-
tribution of selected baseline characteristics is given in Table
1. The distributions of 169 baseline variables (listed in Ap-
pendix) were examined; the treatment differences for 12 of
these (7. 1%) yielded absolute Z values of 1.96 or greater,
a proportion only slightly higher than expected to occur by
chance. The baseline distribution of frequent or complex
cardiac arrhythmia showed some imbalance, with more pa-
tients in the placebo group than in the mexiletine group
having this finding (Z value = - 1.78); the imbalance was
due to the distribution of runs of three or more premature
ventricular complexes. Therefore, in one of the analyses of
this end point, the occurrence of the primary arrhythmia
end point during follow-up was considered for patients with
and without such findings at baseline. A Z value of - 1.96
was obtained for the mexiletine-placebo comparison of an-
other electrocardiogram variable, cardiac arrhythmia (de-
fined in Table 1).
The mean number of days from onset of symptoms of
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Table 1. Selected Baseline Characteristics* by Treatment Group
Mexiletine Placebo
Variable (n = 317) (n = 313) Z Value
Mean age (yr) 56.5 57.1 -0.80
Age 2: 55 yr 57.7 62.0 - 1.09
Male 85.2 81.8 1.14
Cigarette smoker (ever) 82.0 81.8 0.07
Cigarette smoker (current) 59.3 57.8 0.38
Medical history
Prior myocardial infarction 12.9 12.8 0.06
Acute coronary insufficiency 9.8 5.4 2.06
Angina pectoris 41.0 41.2 -0.05
Congestive heart failure 2.5 3.5 -0.73
Diabetes 14.8 9.6 2.01
Stroke 0.9 1.3 -0.40
Events occurring between qualifying event and entry
Acute coronary insufficiency 1.6 0.6 1.12
Angina pectoris 17.0 15.0 0.69
Congestive heart failure 20.2 16.6 1.16
Complete left bundle branch block 0.6 1.0 -0.46
Complete right bundle branch block 0.3 1.6 - 1.66
Second or third degree AV block 7.9 8.0 -0.05
Sinoatrial block 0.6 1.0 -0.46
Multiform premature ventricular complexes 17.0 20.1 -1.00
Atrial flutter or fibrillation, or both 7.9 8.0 -0.05
Ventricular tachycardia or fibrillation 18.0 13.1 1.69
Ventricular asystole 0.9 0.0 1.73
Other arrhythmia 11.4 15.3 -1.47
Any arrhythmia 40.4 45.0 - 1.18
Cardiac arrest 5.4 1.0 3.15
Diarrhea 5.7 2.2 2.21
Medication prescribed between qualifying event and entry
Antiarrhythmic agents (other than digitalis or beta-receptor blocking drugs) 38.8 35.5 0.87
Beta-receptor blocking drugs 20.2 16.6 1.16
Digitalis 16.4 13.1 1.17
Diuretic drugs 40.7 34.2 1.69
Antihypertensive agents (other than diuretic or beta-receptor blocking drugs) 5.4 6.4 -0.55
Anticoagulant agents 72.9 65.8 1.92
Antiplatelet agents 23.7 23.6 0.01
Antianginal agents (including long-acting nitrates and nitroglycerin) 70.7 70.0 0.19
Insulin 5.4 4.8 0.33
Oral hypoglycemic agents 4.1 2.9 0.84
Lipid-lowering drugs 0.9 0.3 0.99
Gout medication 3.5 1.0 2.14
Characteristics at entry
MIRV class It 78.5 79.9 -0.41
Abnormal tendon reflexes 2.2 5.4 -2.11
Mean systolic blood pressure (mm Hg) 115.0 114.8 0.13
Mean diastolic blood pressure (mm Hg) 72.7 72.2 0.69
Mean cholesterol (mg/dl) 221.7 220.2 0.48
Mean weight (kg) 75.0 72.8 2.34
Mean heart rate (beats/min) 74.7 76.2 - 1.69
Baseline 24 hour electrocardiogram
Frequent or complex cardiac arrhythmia 30.7 37.6 -1.78
Cardiac arrhythrniat 41.0 49.0 - 1.96
Premature ventricular complexes (any) 92,0 90.6 0.61
Single only 66.3 57.7 2.17
Doublets but no runs of 3 or more 17,0 20.1 -0.99
Runs of 3 or more 8.7 12.8 - 1.62
Doublets or runs of 3 or more 25.7 32.9 - 1.94
No. of electrocardiograms 300 298
continued
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Table 1. (continued)
Variable
Baseline laboratory measurements
Mean gamma glutamyl transferase (units/liter)
Mean creatinine (mg/dl)
Mean blood urea nitrogen/creatinine ratio
Osmolality serum water (mOsm/kg)
Total bilirubin (mg/dl)
No. 0 f laboratory reports
Mexiletine
(n = 317)
52.2
1.2
16.4
296.3
0.53
298
MEXILETINE
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Placebo
(n = 313)
41.7
1.1
17.5
295.9
0.52
287
1153
Z Value
2.55
2.48
-2.81
0.43
0.85
*Tht: variables listed are those that were considered important risk factors or showed large drug-placebo differences. tMyocardial Infarction Research
Unit class I = no heart failure and no clinical signs of cardiac decompensation (21). tCardiac arrhythmia was defined as the occurrence of five or more
single premature ventricular complexes in anyone of the forty-eight 30 minute blocks or one or more runs of two or more premature ventricular complexes
in the entire 24 hour recording. All values are in percent of patients except where indicated.
the qualifying myocardial infarction to initiation of treat-
ment was 11.2 days in the mexiletine group and ILl days
in the placebo group (range 4 to 24). Overall, the groups
were relatively comparable at baseline study, although an
imbalance with respect to one arrhythmia variable was noted.
There is no evidence that the protocol for issuing treatment
allocations was not followed in the assignment of treatment
to any of the 630 enrolled patients.
Effects ofmexiletine on arrhythmia. Altogether 2,292
ambulatory 24 hour electrocardiograms were obtained (89.6%
of those scheduled). Of these, 66.8% had 23 or more hours
of ana lyzable data, 90.7% had more than 20 hours and 4.6%
(106 tapes) were unanalyzable.
The occurrence offrequent or complex cardiac arrhyth-
mia in the mexiletine and placebo groups at baseline and
follow-up visits with ambulatory 24 hour electrocardiograms
is given in Table 2A. A significant reduction in the occur-
rence of the primary end point was observed in the mexi-
letine group compared with the placebo group at months 1
and 4 after entry, yielding Z values of - 5.04 and - 3.98,
respectively. The corresponding differences at month 12
was in the same direction, but was not significant. There
was a large increase in the number of patients with this end
point at month 1 (58.0%) compared with baseline (37.6%)
in the placebo group. The corresponding change in the mex-
iletine group was much smaller, that is, 36.5% at month I
compared with 30.7% at baseline. In the placebo group, the
percent of patients with frequent or complex cardiac ar-
rhythmia was somewhat lower at month 12 than at months
1 and 4, whereas in the mexiletine group the percent with
this finding was higher at month 12 than at months I or 4.
The occurrence of the primary end point in the cohort of
patients with 24 hour electrocardiograms at baseline and at
months 1, 4 and 12 was also examined; the findings were
very similar to those for all patients. The mexiletine-placebo
differences in the occurrence of frequent or complex cardiac
arrhythmia for patients with and without that finding at entry
were also similar to the differences observed for all patients.
An analysis taking account of deaths in each group is pre-
sented in Table 2B. The findings are essentially the same
as in the previous analyses.
About twice as many patients in the placebo group as in
the mexiletine group had runs of three or more premature
ventricular complexes at months 1 and4; these drug-placebo
differences were statistically significant based on study cri-
teria (Table 2C). At month 12, there was a slightly, but not
significantly, higher percentage of patients with runs of three
or more premature ventricular complexes in the mexiletine
group than in the placebo group. The results for other
electrocardiographic end points are presented in another study
report (20).
Mortality. After an average follow-up of 9 months, there
were 24 deaths (7.6%, standard error = 1.5%) in the mex-
iletine group compared with 15 deaths (4.8%, standard error
= 1.2%) in the placebo group (Z value = 1.45) (Table 3).
Of the 39 reported deaths, 35 were attributed to cardiovas-
cular disease, 21 in the mexiletine group and 14 in the
placebo group. Seven deaths (2.2%) in the mexiletine group
and four deaths (1.3%) in the placebo group were sudden,
that is, occurring within I hour of onset of symptoms.
Life table rates for total mortality were higher in the
mexiletine than in the placebo group (Fig. I). The Cox Z
value for the comparison of these curves was 1.47 (unad-
justed) and 1.47 after adjusting for 10 baseline character-
istics (identified in Appendix).
Mortality was examined among the 17 patients in the
mexiletine group and 3 patients in the placebo group who
had been reported to have cardiac arrest between the onset
of the qualifying myocardial infarction and entry into study.
Only one (a mexiletine-treated patient) of these patients died
during the follow-up period.
Among patients classified as not having frequent or com-
plex cardiac arrhythmia in the baseline 24 hour electro-
cardiogram, 4.8% died in both the mexiletine and placebo
groups (10 of 208 and 9 of 186, respectively). In the group
identified with frequent or complex cardiac arrhythmia, the
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Table 2. Occurrence of Cardiac Arrhythmia End Points by Treatment and Visit
Mexiletine Placebo
No. at No. at
Risk No. % Risk No. % Z Value
A. Occurrence of Frequent or Complex Cardiac Arrhythmia*
All patients
Baseline 300 92 30.7 298 112 37.6 -1.78
I month 266 97 36.5 283 164 58.0 -5.04
4 months 235 98 41.7 242 145 59.9 -3.98
12 months 104 45 43.3 110 59 53.6 -1.52
Ever at I, 4 or 12 months 291 163 56.0 300 209 69.7 -3.44
Patients without frequent or complex cardiac arrhythmia at entry
I month 174 48 27.6 168 85 50.6 -4.36
4 months 153 55 35.9 141 73 51.8 -2.73
12 months 69 26 37.7 67 29 43.3 -0.67
Ever at I, 4 or 12 months 192 94 49.0 176 III 63.1 -2.72
Patients with frequent or complex cardiac arrhythmia at entry
I month 77 42 54.5 102 72 70.6 -2.21
4 months 67 35 52.2 86 65 75.6 -3.01
12 months 29 16 55.2 38 28 73.7 -1.58
Ever at 1,4 or 12 months 82 57 69.5 109 90 82.6 -2.12
B. Occurrence of Frequent or Complex Cardiac Arrhythmia or Death
All patients
Baseline 300 92 30.7 298 112 37.6 -1.78
I month 276 107 38.8 287 168 58.4 -4.69
4 months 254 117 46.1 251 154 61.4 -3.45
12 months 116 57 49.1 118 67 56.8 -1.17
Ever 303 182 60.1 306 217 70.9 -2.82
C. Occurrence of Runs of Three or More Premature Ventricular Complexes
All patients
Baseline 300 26 8.7 298 38 12.8 -1.62
I month 266 25 9.4 283 61 21.6 -3.92
4 months 235 26 11.1 242 50 20.7 -2.86
12 months 104 18 17.3 110 17 15.5 0.37
Ever at I, 4 or 12 months 291 58 19.9 300 98 32.7 -3.51
*Frequent or complex cardiac arrhythmia defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30
minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour recording.
15.2% (14 of 92) died in the mexiletine group and 5.4% (6
of 112) died in the placebo group. The test for homogeneity
yielded a Z value of 1.67. There were 32 patients (17 mex-
iletine-treated and IS placebo-treated) who could not be
classified and were not included in the analysis.
Interaction of treatment with each of 141 baseline vari-
ables was assessed for total mortality rate. The variables
for which there was a suggestion of interaction with treat-
ment were systolic blood pressure and Myocardial Infarction
Research Unit (MIRV) classification (21). Among patients
with a baseline systolic blood pressure of less than l lf mm
Hg, there were 14 deaths (8. 1%) in the mexiletine group
compared with 2 deaths (1.2%) in the placebo group. Cor-
responding results for patients with a systolic blood pressure
of l l S mm Hg or greater were 10 deaths (6.9%) and 13
deaths (8.8%) in the mexiletine and placebo groups, re-
spectively. The test for homogeneity yielded a Z value of
2.44, which was not statistically significant. In patients in
MIRV class I (no heart failure and no signs of cardiac
decompensation), there were 10 deaths (4.0%) in the mex-
iletine group and 12 deaths (4.8%) in the placebo group.
In patients in class II (heart failure) and III (severe heart
failure), there were 14 deaths (20.6%) in the mexiletine
group and 3 deaths (4.8%) in the placebo group. The Z
value of 2.31 for the test for homogeneity was not statis-
tically significant. Among mexiletine-treated patients with
some evidence of heart failure, half had a systolic blood
pressure of less than l lS mm Hg with eight deaths (23.5%)
and half had a systolic blood pressure of l lS mm Hg or
greater with six deaths (17.6%). Approximately half of the
63 placebo-treated patients with some evidence of heart
failure had a systolic blood pressure of l l S mm Hg or greater
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Table 3. Cause-Specific Mortality by Treatment Group as Classified by Mortality and Morbidity
Classification Committee
Mexiletine (n = 317) Placebo (n = 313)
No. of Mortality No. of Mortality
Cause of Death Deaths (%) Deaths (%) Z Value
All deaths 24 7.6 15 4.8 1.45
Cardiovascular disease 21 6.6 14 4.5 1.18
Coronary heart disease 18 5.7 12 3.8 1.09
with recent event
Sudden* 7 2.2 4 1.3 0.89
Nonsudden 11 3.5 8 2.6 0.67
Coronary heart disease 3 0.9 2 0.6 0.44
without recent event
Noncardiovascular diseaset 3 0.9 0.3 0.99
*Deaths occurring within I hour of the onset of symptoms. tNoncardiovascular causes of death: in mexiletine
group = perforated duodenual ulcer, cancer of liver or pulmonary disease; in placebo group = suicide.
with three deaths (9.7%). There were no deaths in the pla-
cebo group with some evidence of heart failure and a low
systolic blood pressure at baseline.
Other events including side effects. Findings for other
fatal and nonfatal events are given in Table 4. Fewer patients
in the mexiletine group than in the placebo group were
hospitalized for angina pectoris (Z value = - 1.58) or car-
diovascular surgery (Z value = - 1.68). More mexiletine-
than placebo-treated patients had pulmonary embolism (Z
value == 1.99). None of these differences was statistically
significant. Life table rates for incidence of coronary events
(coronary death or nonfatal myocardial infarction) showed
no treatment differences (Fig. 2).
In regard to use ofnonstudy medication during the trial,
more rnexiletine- than placebo-treated patients reported us-
ing tricyclic antidepressants or hypnotics, sedatives and bar-
biturates (Table 5). Patient complaints occurred almost as
frequently in the placebo group as in the mexiletine group
(Table 6). Significantly more mexiletine- than placebo-treated
patients complained of tremor and loss of consciousness,
nausea and constipation; these differences were of border-
line significance.
Follow-up and adherence. Of the 630 patients enrolled,
566 completed the final visit and 39 were reported to have
died. The remaining 25 patients were known to be alive as
of August 31, 1982. Overall, 93.8% of all scheduled visits
were completed, 92.9% in the mexiletine group and 94.6%
in the placebo group.
Adherence to assigned study medication was assessed at
each follow-up visit by pill count, questioning the patient
and analysis of serum mexiletine levels. It was estimated
that 12.7% of patients in the mexiletine group and 9.9% of
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Table 4. Percent of Patients With Specified Fatal and Nonfatal Events
Mexiletine (n = 317)
%
No. of
Events %
Placebo (n = 313)
No, of
Events Z Value
A. Events as Classified by the Mortality and Morbidity Classification Committee
Definite nonfatal myocardial infarction 13 4 . 1 18 5.8 - 0.96
Definite acute coronary insufficiency 4 1.3 I 0.3 1.33
Definite angina pectoris with 10 3.2 18 5.8 - 1.58
hospitalization
Definite stroke 3 0.9 I 0.3 0.99
Coronary incidence* 31 9.8 29 9.3 0.22
B. Additional Events Reported by Clinic Physician
Definitecongestive heart failure 34 10,7 26 8.3 1.03
Definite pulmonaryembolism 4 1.3 0 0.0 1.99
Cardiovascularsurgery 15 4,7 25 8.0 - 1.68
*Coronary death or definite nonfatal myocardial infarction.
patients in the placebo group took less than 10% of study
medication at 50% or more of all visits. For the mexiletine
group 76.3% and for the placebo group 83.1% of the patients
were on full dosage at the last completed follow-up visit
before the final visit.
The major reasons why study medication was reduced
or discontinued in the mexiletine group were tremors , in-
somnia, epigastric pain and nausea (Table 7). The main
reason for reduced dosage or stopping medication in the
placebo group was antiarrhythmic treatment not including
beta-receptor blocking agents.
Blood specimens were taken at each follow-up visit and
forwarded to the Central Laboratory for measurement of serum
mexiletine levels. Twenty-five percent of patients in the
mexiletine group had serum mexiletine levels of 0.7 jLg/ml
or greater (presumed therapeutic level) for at least 75% of
all visits and 16.4% had serum mexiletine values of 0.2
jLg/ml or less for at least 75% or more of all follow-up visits
(Table 8). A few patients (6.7%) in the placebo group had
serum mexiletine values greater than 0. 2 jLg/ml. An external
quality control program included submission of two aliquots
of the same specimen at different time periods for analysis
at the Central Laboratory. For one pair of the 36 placebo
pairs submitted , the test for mexiletine was positive in one
of the two aliquots of the same specimen , but not the other .
Occurrence of events in subgroups classified by as-
sessment of adherence. For the mexiletine-treated patients
with a serum mexiletine level of 0.7 jLg/ml or greater, the
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Table 5. Percent of Patients Taking Nonstudy Medication at Any Time During the Trial
Mexiletine Placebo
Medication (n = 317) (n = 313) Z Value
Antiarrythmic agents (other than digitalis or 5.7 6.1 -0.21
beta-receptor blocking drugs)
Beta-receptor blocking drugs 30.3 25.9 1.23
Digitalis 23.7 17.9 1.78
Diuretic drugs 45.1 41.9 0.82
Antihypertensive agents (other than diuretic 8.2 9.6 -0.61
and beta-receptor blocking drugs)
Anticoagulant agents 32.5 32.3 0.06
Antiplatelet agents 24.6 19.8 1.45
Antianginal agents (including long-acting 66.2 69.0 -0.74
nitrates and nitroglycerin)
Insulin 4.7 2.6 1.46
Oral hypoglycemic agents 5.4 3.8 0.92
Lipid-lowering drugs 2.8 2.2 0.48
Tricyclic antidepressants 1.9 0.0 2.45
Tranquilizers 45.7 44.7 0.26
Hypnotics, sedatives , barbiturates 36.0 28.1 2.11
occurrence of frequent or complex cardiac arrhythmia at
month I was 28.2% compared with 48.3% for patients with
a serum mexiletine level of 0 .2 ILg/ml or less (Table 9).
These findings must be interpreted with caut ion since there
is no assurance that patients with a high level of serum
mexiletine were comparable with those patients with a low
Table 6. Percent of Patients Ever Complaining of Specific Types of Problems
Du ring FOllow-Up
Mexiletine Placebo
Reported Problems (n = 317) (n = 313) Z Value
Neuropsychiatric
Dizziness 30.0 27.5 0.69
Loss of consciousness 4.7 1.3 2.54
Headaches 28.4 26.8 0.44
Weakness 36.0 34.8 0.30
Visual disturbances 16.1 14.4 0.60
Ringing of the ears 17.3 17.3 0.0
Tremor 3\.2 13.4 5.48
Paresthesia 20.5 20.4 0.02
Convulsions 0.6 0.0 1.41
Insomnia 48.6 40.9 1.94
Nightmares 16.4 14.4 0.70
Depressive state 15.5 19.2 -1.23
Hallucinations 0.6 1.0 -0.46
Ataxia 2.8 3.5 -0.48
Dysarthria 1.9 1.3 0.62
Psychotic state 0.3 0.3 0.0
Other mental disturbances 3.2 1.3 1.60
Parkinsonism 1.3 0.6 0.80
Gastrointestinal
Epigastric pain 27.4 24.6 0.81
Nausea 23.3 14.7 2.78
Diarrhea 15.8 14.4 0.49
Constipation 30.3 20.1 2.95
Cardiovascular
Hypotension 1.9 4.5 -1.85
Other
Frequent urination 26.8 25.9 0.27
Sexual problems 12.3 8.0 1.79
Any of the above 88.0 85.0 1.\1
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Reasons at Any Time
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Reasons
Neuropsychiatric
Parkinsonism
Tremors
Paresthesia
Dizziness
Loss of consciousness
Insomnia
Weakness
Depression
Other mental disturbances
Ataxia
Dysarthria
Headache
Visual disturbances
Ringing of the ears
Nightmares
Cardiovascular
Cardiac insufficiency
Second or third degree AV block
Ventricular tachycardia or fibrillation
Other conduction disturbance
Congestive heart failure (not controlled
by digitalis or diuretic drugs)
Hypotension
Beta-receptor blocking drug therapy
Antiarrhythmic therapy
Antianginal therapy
Gastrointestinal
Epigastric pain
Nausea
Diarrhea
Constipation
Other
Hypersensitivity to medication
Treatment unblinded
Unexplained morbid state
Frequent urination
Sexual problems
Rash
Hospitalization
Missed visit
Other
Any of the above
Mexiletine Placebo
(n = 317) (n = 313) Z Value
0.9 0.0 1.73
6.0 0.6 3.74
2.2 0.6 1.66
4.7 1.9 1.97
0.9 0.0 l.7.3
6.9 1.9 3.06
4.4 2.6 1.27
0.9 0.3 0.99
1.3 0.0 1.99
0.3 0.3 0.0
0.3 0.0 0.99
1.3 1.0 0.36
1.3 1.3 0.0
1.3 0.3 1.33
1.9 1.0 0.99
1.6 1.6 0.0
0.3 0.0 0.99
1.6 1.3 0.32
0.3 0.3 0.0
0.3 1.0 -1.02
0.3 0.6 -0.59
2.2 2.6 -0.29
3.5 5.4 -1.19
2.5 3.8 -0.94
6.3 4.2 1.21
10.7 3.5 3.51
1.3 i.3 0.0
4.1 0.6 2.85
0.0 0.3 -1.00
0.6 0.6 0.0
0.6 0.3 0.57
0.6 0.6 0.0
1.3 0.6 0.80
0.0 1.0 - 1.75
5.4 7.0 -0.87
1.9 1.3 0.62
10.1 8.6 0.63
36.6 28. I 2.27
versus 71.7%, respectively). Thus, it larger drug-placebo
difference in occurrence of this arrhythmia end point was
observed in good compared with poor adherers (21.2 versus
Table 8. Percent Distribution of Patients by Serum
Mexiletine Levels
level of serum mexiletine. In addition, many patients could
not be classified (76 in the mexiletine group and 53 in the
placebo group).
Occurrence offrequent or complex cardiac arrhythmia
at any follow-up visit (at months 1,4 or 12) was determined
for patients with good and with poor adherence (Table 10).
The former was defined as 90% adherence to full prescrip-
tion at months 1, 4 and 12. The percent of mexiletine-treated
patients with the primary arrhythmia end point at any visit
was less for good adherers than for poor adherers (45,2
versus 57.8%, respectively). Little difference was noted for
good and poor adherers among placebo-treated patients (65.4
Serum Mexiletine Levels 75% or
More: of All Follow-Up Visits
a ~ 0.7 p,g/ml
b Neither a nor c
c ,;; 0.2 p,g/ml
Mexiletine
(n = 293)
25.3
58.4
16.4
Placebo
(n = 296)
0.3
6.4
93.2
lACC Vol 4. No.6
December J984: J 148~63
MEXILETINE
IMPACT RESEARCH GROUP
1159
Table 9. Occurrence of Frequent or Complex Cardiac Arrhythmia by Serum Mexiletine Level at
I Month Follow-Up Visit
Mexiletine (n = 317) Placebo (n = 313)
Serum Mexiletine No. at No. at
Levels Risk No. % Risk No. %
'" 0.7 J-Lg/ml 110 31 28.2 4 3 75.0
0.3 to 0.6 J-Lg/ml 71 26 36.6 14 9 64.3
~ 0. 2 J-Lg/rill 60 29 48.3 242 142 58.7
Cannot classify* 76 53
*Patients who did not have I month follow-up visit serum mexiletine value and 1 month follow-up visit
24 hour electrocardiogram .
13.9% respectively). The same cautionary note as men-
tioned for the analysis of the biochemical adherence as-
sessment applies to this analysis .
Discussion
Effect on cardiac arrhythmia. Overall , the results for
the primary cardiac arrhythmia end point indicate that mex-
iletine was quite effecti ve in reducing the risk of arrhythmia
during the first 4 months after discharge from the hospital.
The differences were primaril y due to the large increase
compared with baseline in the percent of placebo-treated
patient" with this end point at I and 4 months after entry ;
approximately 60% at months I and 4 compared with 38%
before initiation of treatment. The increase in the occurrence
of arrhythmia after discharge from hospital has been ob-
served by others (9 ,22). Although there were 20 more pa-
tients In the placebo-treated group than in the rnexiletine
group who had frequent or complex cardiac arrhythmia be-
fore the initiation of treatment, this difference did not ac-
count for the large and statistically significant differences
observed during the follow-up visits.
Effect on mortality. The marked difference in occur-
rence of frequent or complex cardiac arrhythmia in mexi-
letine-treated patients compared with the placebo-treated
patients was not accompanied by a reduced mortality rate .
The percent of patients who died was 7.6 and 4.8% in the
mexiletine and placebo groups, respectively; this difference
was not statistically significant.
The mortality results for a large number of subgroups
defined by baseline characteristics were examined to deter-
mine whether any group showed favorable trends or ap-
peared adversely affected by mexiletine treatment. These
analyses showed a larger mexiletin e-placebo difference if
patients had some evidence of heart failure (MIRU class II
or III) or a systolic blood pressure of less than liS mm Hg,
or both , than if these clinical findings were not present , but
the log odds ratio tests for interaction were not significant.
Thus, these findings are suggestive, but not conclusive .
Side effects. More patients in the mexiletine than in the
placebo group reported central nervous system and gas-
trointestinal problems and used more medication for central
nervous system problems. These adverse reactions have been
observed in previous studies of mexilet ine (4- 7,9), but the
occurrence of side effect s severe enough to result in reducing
dosage or stopping the sustained release form of the drug
was less than that reported in studies that used the regular
form of the drug (4-7,9). No previously unreported side
effects were observed in this study.
Serum drug levels. Serum mexiletine levels were gen-
erally lower than those observed in studies with the regular
form of the drug reportin g comparable data (5- 7,9) and
substantially lower than those observed in a short-term study
of the sustained release form (8). There is no obvious ex-
Table 10. Frequent or Complex Cardiac Arrhythmia at I. 4 or 12 Months by
Combined Adherence
Mexiletine (n = 317) Placebo (n = 313)
No. at No. at
Adherence Risk No. % Risk No. %
Good 186 84 45.2 208 136 65.4
Poor 102 59 57.8 92 66 7 1.7
Cannot classify* 29 13
*Patients who did not have at least one follow-up visit adherence value and at least one follow-up visit 24
hour electrocard iogram. Good = 90% adherence and prescription = two capsules at all visits (I , 4 or 12
months) with adherence items answered. Poor = less than 90% or less than two capsules at anyone of the
follow-up visits at month I. 4 or 12.
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planation for the low serum levels observed in IMPACT.
Despite low serum levels, mexiletine-treated patients had
significantly less cardiac arrhythmia at months 1 and 4 than
did placebo-treated patients. It would have been desirable
to have had blood specimens taken for measuring serum
mexiletine levels and 24 hour electrocardiographic record-
ings at the end of the first 3 days of treatment and before
hospital discharge. These procedures would have provided
useful information to define the levels of serum mexiletine
associated with antiarrhythmic effects.
Results of other studies compared with IMPACT.
Findings observed in IMPACt on the occurrence of frequent
or complex cardiac arrhythmia at months 1 and 4 were
similar to those in the placebo-controlled trial of mexiletine
conducted in the United Kingdom (9) in patients at high
risk of sudden death. In that study, the hourly number of
premature ventricular complexes was significantly reduced
by mexiletine at 1 and 3 months after initiation of treatment.
Doublets and multiform beats were also significantly less
frequent in the mexiletine than in the placebo group 1 month
after entry. In this study, after 3 months of treatment and
4 months of follow-up study, there were 13.2 and 11.6%
in mexiletine and placebo groups, respectively. An unfa-
vorable trend in mortality was also observed in IMPACT
mexiletine-treated patients who were in MIRU class II and
III. Observed life table cumulative mortality rate for all
patients at the end of 4 months in IMPACT was 5.5% in
the mexiletine group and 3.0% in the placebo group. At the
end of 12 months, the life table cumulative mortality rate
in the mexiletine and placebo groups in IMPACT was 9.1
and 6.3%, respectively.
A review by May et al. (23) of clinical trials assessing
short-term intervention after myocardial infarction was pub-
lished in 1983. These investigators summarized the studies
of antiarrhythmic drugs as follows: four antiarrhythmic drugs
(disopyraniide, lidocaine, procainamide and quinidine) were
evaluated in 14 trials that satisfied minimal review criteria
(a total study size of at least 100 patients, with random
assignmerit of participants to treatment). Each agent was
reported to suppress ventricular arrhythmia during the acute
phase of a myocardial infarction. Not one of the trials dem-
onstrated that suppression of arrhythmia was accompanied
by a statistically significant reduction in the overall mortality
rate. Most of the trials randomized fewer than 250 patients
and, therefore, these studies had little power to detect dif-
ferences in mortality unless the true difference was 40% or
greater. A review (24) of long-term controlled trials pub-
lished in 1983 considered six clinical trials of antiarrhythmic
agents (aprindine, mexiletine, phenytoin and tocainide) in
patients with myocardial infarction. In four trials in which
cardiac rhythm was monitored, the drugs tested were re-
ported to be effective in reducing occurrence of ventricular
arrhythmias and ectopic beats. Despite that finding, there
was no statistically significant evidence that antiarrhythmic
therapy prolonged life in these patients with myocardial
infarction. Two trials showed a favorable trend in mortality.
All but one study randomized fewer than 250 patients to
each treatment group and, thus, these studies would only
detect large differences in the overall mortality rate.
Three controlled trials (25-27) have shown a significant
reduction in the total mortality rate and sudden death in
patients treated after myocardial infarction with beta-recep-
tor blocking drugs compared with patients treated with pla-
cebo. One recent trial (28) had a favorable trend and another
(29) showed no difference. It is unclear whether the reduc-
tions in mortality rate were due to the antiarrhythmic effects
of the beta-receptor blocking agent or some other action.
Conclusions. IMPACT as well as other studies have
demonstrated the antiarrhythmic efficacy of mexiletine, but
the mortality findings suggest that the suppression of ven-
tricular premature complexes and arrhythmias in patients
after myocardial infarction may not result in a reduced mor-
tality rate. This is in contrast to treatment with beta-receptor
blocking agents, where an antiarrhythmic effect may be one
of the goals. IMPACT did not address the question of whether
patients treated after myocardial infarction with beta-recep-
tor blocking drugs compared with patients treated with pla-
cebo. One recent trial (28) had a favorable trend and another
(29) showed no difference. It is unclear whether the reduc-
tions in mortality rate were due to the antiarrhythmic effects
of the beta-receptor blocking agent or some other action.
Appendix
IMPACT List of 169 Possible Baseline
Adjusting Variables
Characteristics at Entry
Age at entry
Sex, male
Class I electrocardiogram
Time from onset to entry
Myocardial Infarction Research Unit
class II or III
Cigarette smoker (ever)
Cigarette smoker (current)
Cigar smoker (current)
Pipe smoker (current)
Employment (not working)
Life style (sedentary or light)
Suspected or Definite History of Events at Qualifying Visit
Prior myocardial infarction
*Acute coronary insufficiency
*Angina pectoris
Congestive heart failure
Pulmonary embolism
*Variables used in Cox adjusted analysis; acute coronary insufficiency
at qualifying visit or baseline study combined as one variable.
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Peripheral arterial occlusion
Intermittent cerebral ischemic attack
Stroke
Thrombophlebitis
Arterial aneurysm
Intermittent claudication
History of Other Diseases or Conditions at Qualifying Visit
Diabetes mellitus
Bronchial asthma
Rheumatic heart disease
Gastrointestinal disorder
GOUI
Renal disease
Hepatobiliary disease
Hyperlipidemia
Hypertension
Electrocardiographically Documented Arrhythmias or
Conduction Disturbances-Baseline Study
I, Atrial flutter or fibrillation, or both
2, Second or third degree AV block
3. Complete left bundle branch block
4, Complete right bundle branch block
5. Sinoatrial block
6. Ventricular tachycardia or fibrillation
7, Any multiform premature ventricular complexes
8. Ventricular asystole
9. Other arrhythmias
10. Any arrhythmia
Events Occurring Between Qualifying Myocardial Infarction
and Entry-Baseline Study
*Acute coronary insufficiency
Angina pectoris
"Congestive heart failure
Pulmonary embolism
Peripheral arterial occlusion
Intermittent cerebral ischemic attack
Stroke
Thrombophlebitis
Arterial aneurysm
Arrhythmia (not merely premature complex)
Shock
Cardiac arrest
Acute congestive heart failure
Extension of infarction
Pericardia] friction rub
Thn unboembolism
Problems-Baseline Study
I , Dizziness
2. Loss of consciousness
3. Headaches
4. Weakness
5. Visual disturbances
6. Ringing of the ears
7. Tremor
8, Paresthesia
9. Convulsions
*Vanables used in Cox adjusted analysis; acute coronary insufficiency
at qualifying visit or baseline study combined as one variable.
10. Insomnia
II . Nightmares
12. Depressive state
13. Hallucinations
14. Epigastric pain
15. Nausea
16. Diarrhea
17. Constipation
18. Frequent urination
19. Sexual problems
20. Hypotension
21. Ataxia
22. Dysarthria
23. Psychotic state
24. Other mental disturbances
25. Parkinsonism
Medication Prescribed Between Qualifying Event and Entry-
Baseline Study
I . Beta-receptor blocking drugs
2. *Antiarrhythmicagents (other than digitalis or beta-receptor
blocking drugs)
3. Long-term antianginal medication (other than long-acting
nitrates and beta-receptor blocking drugs)
4. Long-acting nitrates
5. Anticoagulant agents
6. Nitroglycerin or other coronary vasodilators
7. Digitalis
8. Diuretic drugs
9. Antihypertensive agents (other than diuretic drugs and beta-
receptor blocking drugs)
10. Antihyperlipidemic agents
II. Aspirin or aspirin-containing compounds
12. Dipyridamole
13. Suifinpyrazone
14. Ticlopidine
15. Other platelet-affecting drugs
16. Oral hypoglycemic agents
17. Insulin
18. Gout medication (other than sulfinpyrazone)
19. Tricyclic antidepressants
20. Tranquilizers
21. Hypnotics, sedatives, barbiturates
22. Vitamins
23. Estrogens or estrogen/progesterone
24. Antihistamines
25. Other prescription drugs
Findings-Baseline Study
I . Peripheral edema
2. Rales
3. Hepatomegaly
4. Splenomegaly
5. Abnormal tendon reflexes
6. Resting tremor
7. Intention tremor
8. Muscular rigidity
9. Other neurologic problem
10. Abnormal cardiac auscultation
11 . Abnormality on chest X-ray film
12. Cardiomegaly
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Physical Examination-Baseline Study
Systolic blood pressure
Diastolic blood pressure
*Heart rate
Weight
Local Laboratory Measurements-Baseline Study
Hematocrit
White blood count
Hematuria
Urine glucose
Urine protein
System Problems-Baseline Study
I. Gastrointestinal
2. Genitourinary
3. Nervous
4. Musculoskeletal
5. Dermal
6. Bronchopulmonary
7. Optic
8. Otic
24 Hour Electrocardiogram
*Cardiac arrhythmia
Frequent or complex cardiac arrhythmia
Doublets or runs
*Runs
Premature ventricular complexes (any)
Single premature ventricular complexes
Doublets but no runs
Central Laboratory Tests-Baseline Level
O. Mexiletine
I. Alkaline phosphatase
2. Gamma glutamyl transferase
3. Serum glutamic oxaloaceticacid transaminase
4. Serum glutamic pyruvic transaminase
5. Glucose
6. Triglycerides
7. Cholesterol
8. Sodium
9. Potassium
10. Chloride
11. Carbon dioxide content
12. Calcium
13. Inorganic phosphorus
14. Uric acid
15. Urea nitrogen
16. Creatinine
17. Total protein
18. Albumin
19. Globulin
20. Albumin/globulin ratio
21. *Blood urea nitrogen/creatinine
22. Anion gap
23. *Osmolality serum water
24. Calcium (ionized)
25. *Total bilirubin
*Variables used in Cox adjusted analysis; acute coronary insufficiency
at qualifying visit or baseline study combined as one variable.
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